Sorbinil

Sorbinil

Sorbinil is an aldose reductase inhibitor used in the management of diabetic complications. It is a synthetic, non-nucleoside, and specific inhibitor of aldose reductase, an enzyme involved in the polyol pathway that plays a significant role in the development of diabetic complications.

Pharmacology

Sorbinil acts by inhibiting the enzyme aldose reductase, which is responsible for the conversion of glucose to sorbitol. This enzyme is part of the polyol pathway, a metabolic pathway that becomes hyperactive in individuals with poorly controlled diabetes. The accumulation of sorbitol within cells can lead to various diabetic complications, including diabetic neuropathy, diabetic retinopathy, and diabetic nephropathy. By inhibiting aldose reductase, sorbinil prevents the accumulation of sorbitol, thereby reducing the risk of these complications.

Clinical Use

Sorbinil has been used in the management of various diabetic complications, particularly those affecting the eyes and nerves. It has been shown to be effective in reducing the progression of diabetic retinopathy and diabetic neuropathy. However, its use has been limited due to potential side effects, including allergic reactions and liver toxicity.

Side Effects

The most common side effects of sorbinil include nausea, vomiting, and abdominal pain. In rare cases, it can cause serious allergic reactions, including anaphylaxis. It has also been associated with liver toxicity, which can lead to hepatitis or liver failure in severe cases.

See Also

• Aldose reductase inhibitor
• Diabetic complications
• Polyol pathway

‎